Ideogen AG and FarmaMondo enter into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive partner for their innovative PTCL (Peripheral T-cell lymphoma) and Limphoblastic Leukemia portfolio drugs: Folotyn, Beleodaq and Marqibo.
READ MORE
On June 2021 Ideogen AG and FarmaMondo entered into an exclusive Managed Access Program distribution agreement appointing the FarmaMondo Group as the exclusive partner to make their innovative products: Folotyn, Beleodaq and Marqibo (vinCRIStine sulfate LIPOSOME injection) available for patients affected by PTCL pathology (Peripheral T-cell lymphoma, a diverse group of aggressive lymphomas that develop from mature-stage white blood cells called T-cells and natural killer (NK) cells. PTCL is classified as a subtype of non-Hodgkin’s lymphoma) and Limphoblastic Leukemia in Russia, CIS and Baltics.
The agreement appoints FarmaMondo as the exclusive provider of access for those patients with unmet need through a Named Patient Managed Access Program.
FOLOTYN® is indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
BELEODAQ is a histone deacetylase inhibitor indicated for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL)
Marqibo is a vinCRIStine sulfate LIPOSOME injection, indicated for the treatment of adult patients with Philadelphia chromosome–negative (Ph‒) acute lymphoblastic leukemia (ALL) in second or greater relapse or whose disease has progressed following 2 or more anti-leukemia therapies.
ABOUT FARMAMONDO
FarmaMondo is a Swiss-headquartered pharmaceutical group focused on providing market access and specialty distribution services, through a unique infrastructure and geographical footprint targeted to providing access to medicines across unlicensed and licensed phases.
For more information about FarmaMondo please visit www.farmamondo.com.
ABOUT IDEOGEN AG
Ideogen AG is a specialty-care focused pharmaceutical offering healthcare providers access to unique treatment options in Oncology, Hematology, Infectious Disease, Nephrology and Rare-Diseases across the European Union, Middle East & North African Region.
As a partner to global pharmaceutical R&D companies, we provide them a spring board in accessing the Swiss pharmaceutical market with our experienced team and extensive industry know-how.
For more information about Ideogen please visit: www.ideogen.ch
